Prevalence of HIV-associated Co-infections and Clinical Characteristics among HIV/AIDS Outpatients in the Context of Dolutegravir Roll-out Program in Vietnam

Download Article

DOI: 10.21522/TIJPH.2013.10.02.Art021

Authors : Thanh Nguyen Tat, Dat Nguyen Tat


The prevalence of significant HIV-associated co-infections and clinical data of HIV/AIDS outpatients in the context of dolutegravir (DTG) transition are sparsely reported in Vietnam. Treatments of HIV co-infection, including antifungals, anti-tuberculous drugs, and direct-acting antiviral agents for viral hepatitis C, potentially challenge the efficacy of DTG-based therapies in terms of drug-to-drug interactions. We conducted a single-center, cross-sectional study between June and October 2020 in Ho Chi Minh City, Vietnam. HIV-infected outpatients were enrolled in the study when they attended the clinic to receive medical consultations and antiretroviral therapy (ART). Descriptive analyses were performed to describe the data. A total of 406 HIV-infected participants were enrolled in the study. The prevalence of HIV co-infected with chronic viral hepatitis B and C were 9.9% and 10.6%, respectively. Approximately 22.2% of HIV-infected patients had a history of tuberculosis treatment, and roughly 9% of participants experienced invasive fungal infections, mainly cryptococcosis, taralomycosis, and Pneumocystic jirovecii pneumonia. History of sexually transmitted diseases accounted for 40.4%. At the time of DTG transition, roughly 93% of patients were clinically stable, with a median CD4 count of 603 cells/µl. Two-thirds of HIV-infected patients achieved viral suppression (HIV viral load threshold < 20 copies/ml). A total of thirteen (3.2%) patients were ongoingly undertaking protease-inhibitors-based second-line ART regimens. The ART adherence was assessed at 92.1%. The prevalence of HIV-associated co-infections is still high in the context of DTG transition in Vietnam. More effort is needed in order to achieve the UNAIDS 90-90-90 targets.

Keywords: Dolutegravir, Invasive fungal infections, Tuberculosis, Viral hepatitis, Vietnam.


[1] Global HIV and AIDS statistics | Avert 2020. [Internet]. Available from: [(Accessed and cited on 12 March 2021].

[2] World Health Organization. Transition to new antiretroviral drugs in HIV programmes: clinical and programmatic considerations. Geneva: 2017. [Internet]. [Accessed and cited on 20 June 2021]. Available from:

[3] WHO report 2018 on Dolutegravir program [Internet]. [(Accessed and cited 20 on June 2021]. Available from:

[4] Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018; 5: e400-e404.

[5] UNAIDS. New high-quality antiretroviral therapy to be launched in South Africa, Kenya, and over 90 low- and middle-income countries at a reduced price, 2017 [Internet]. [Accessed and cited on 20 June 2021]. Available from:

[6] Ho Chi Minh City, Vietnam Metro Area Population 2021. [Internet]. [Accessed and cited on 20 June 2021]. Available from:

[7] Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition. Geneva: World Health Organization; 2016. ANNEX 10, WHO clinical staging of HIV disease in adults, adolescents, and children. [Internet]. [Accessed and cited on 20 June 2021]. Available from:

[8] 90–90–90—An ambitious treatment target to help end the AIDS epidemic | UNAIDS [Internet]. (Accessed and cited on 15 July 2021). Available from

[9] Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. Afr Health Sci. 2016; 16:588-95.

[10] Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011; 52:945-52.

[11] Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17:873-881.

[12] Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019; 22 Suppl 6: e25355.

[13] Sharma V, Ramachandran VG, Mogha NS, Bharadwaj M. Hepatitis B & C virus infection in HIV seropositive individuals & their association with risk factors: A hospital-based study. Indian J Med Res. 2018; 147:588-593.

[14] Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B, and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005; 19:593-601.

[15] Kerubo G, Khamadi S, Okoth V, Madise N, Ezeh A, Ziraba A, et al. Hepatitis B, Hepatitis C and HIV-1 Coinfection in Two Informal Urban Settlements in Nairobi, Kenya. Plos One. 2015; 10: e0129247.

[16] Khatib A, Matiko E, Khalid F, Welty S, Ali A, Othman A, et al. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health. 2017 ;17: 917.

[17] Nnakenyi ID, Uchechukwu C, Nto-Ezimah U. Prevalence of hepatitis B and C virus co-infection in HIV positive patients attending a health institution in southeast Nigeria. Afr Health Sci. 2020; 20:579-586.

[18] Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192: 992-1002.

[19] Kumar R, Singla V, Kacharya Sk. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. Trop Gastroenterol. 2008; 29:136-47.

[20] Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first-line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Health Res Policy. 2019; 4:32.

[21] Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N, et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017; 72: 3141-3148.

[22] Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016; 71:2918-27.

[23] Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. Plos one. 2019; 14: e0211344.

[24] Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010; 10:155-66.

[25] Bain LE, Nkoke C, Noubiap JJN. UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades”. BMJ Glob Health. 2017; 2: e000227.

[26] Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020; 70: 549-556.

[27] Vadlapatla RK, Patel M, Paturi DK, Pal D, Mitra AK. Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol. 2014; 10:561-80.

[28] Tivicay (Dolutegravir) Package Insert. Research Triangle Park, NC: GlaxoSmithKline; 2013.